Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Edwards Lifesciences

Edwards Lifesciences Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Investors Business Daily

Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector?

As Edwards Lifesciences outshines the broader healthcare sector, Wall Street remains optimistic about its prospects.

Barchart

Edwards Lifesciences Stock Pumps Up Its Relative Strength Rating

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Edwards Lifesciences Stock: Analyst Estimates & Ratings

Though Edwards Lifesciences has outperformed the SPX over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market

The Federal Trade Commission (FTC) on Wednesday moved to block medical device supplier Edwards Lifesciences Corp.'s (NYSE:EW) proposed acquisition of JenaValve Technology, Inc.

Benzinga

Stocks With Rising Relative Strength: Edwards Lifesciences

Edwards Lifesciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance

Edwards Lifesciences’ (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Dow, S&P Climb On Trump-China Deal Hopes; Cathie Wood Loads Up On Tesla Stock (Live Coverage)

The Dow Jones index rose after surprise economic data. Tesla stock rallied on new plans to launch its robotaxi service.

Investors Business Daily

How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter

Edwards Lifesciences stock surged Friday after the medtech hiked its outlook following a key setback for rival Boston Scientific.

Investors Business Daily

Is Edwards Lifesciences Stock Underperforming the Dow?

Despite Edwards Lifesciences’ underperformance relative to the broader Dow over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Edwards Lifesciences Sees IBD RS Rating Rise To 71

Edwards Lifesciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Edwards Lifesciences Getting Closer To Key Technical Measure

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Investors Business Daily

How Boston Scientific's Surprise Setback Bolstered Two Of Its Top Rivals

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

Investors Business Daily

Do Wall Street Analysts Like Edwards Lifesciences Stock?

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Edwards Shoots Higher As It Shrugs Off Tariffs Worries — Until 2026

Edwards stock shot higher Thursday after the medtech player said tariffs are likely to have little impact in 2025.

Investors Business Daily

Edwards Makes A Bullish Move As Heart-Valve Replacements Top $1 Billion

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Barchart

Is Edwards Lifesciences Stock Underperforming the S&P 500?

Edwards Lifesciences has recently underperformed the broader S&P 500, yet analysts remain moderately optimistic about the stock's potential.

Benzinga

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Edwards Skids On Weak Expectations For Its Bread-And-Butter Moneymaker

Edwards Lifesciences stock fell Friday after the company said its TAVR segment will face numerous challenges in the fourth quarter.

Barchart

How Is Edwards Lifesciences' Stock Performance Compared to Other Medical Devices Stocks?

While Edwards Lifesciences has underperformed the broader medical devices industry recently, analysts are moderately bullish on the stock's prospects.

Barchart

Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?

Despite Edwards Lifesciences’ underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Investors Business Daily

Edwards Crashes 31% After Slashing Guidance For Its Biggest Moneymaker

Edwards Lifesciences stock plummeted Thursday after the medtech cut its outlook for TAVR sales following a mixed second-quarter report.

Barchart

What You Need to Know Ahead of Edwards Lifesciences' Earnings Release

Edwards Lifesciences is expected to release its second-quarter earnings this month, and analysts expect a single-digit profit increase.

Investors Business Daily

Edwards Lifesciences Trying To Close In On Key Technical Measure

Edwards Lifesciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Barchart

Edwards Lifesciences Stock: Is EW Underperforming the Healthcare Sector?

Edwards Lifesciences has recently underperformed the Healthcare sector, but Wall Street analysts anticipate a modest upside for the stock.

1 2 3 4

People

Margaret Kaczor Andrew

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Federal Trade Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.